Clinical Trials in Maryland

Showing 8321-8340 of 17,687 trials

CVR Registry Evaluating Flexitouch Plus and Conservative Care vs Conservative Care Only for Treatment of Lymphedema

NCT04116099

Subjects with lower extremity lymphedema will be prescribed, per standard of care, to either Flexitouch Plus with conservative care or conservative care only and be followed for 12 months.

Lymphedema

Tactile Medical63 participantsStarted Oct 2019

Glen Burnie, Maryland, United States • Greenbelt, Maryland, United States • Silver Spring, Maryland, United States

COMPLETED9.2 miles

Tailoring Mindfulness Interventions for Families Managing Chronic Health Conditions

NCT05271851

This is not an intervention or treatment study. It is an observational qualitative data study about tailoring a mindfulness intervention to assist families managing chronic health conditions.

MindfulnessChronic Disease

University of Maryland, College Park34 participantsStarted Mar 2020

College Park, Maryland, United States

COMPLETEDPhase 312 miles

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

NCT02198794

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.

Tardive Dyskinesia

Auspex Pharmaceuticals, Inc.343 participantsStarted Oct 2014

Tuscaloosa, Alabama, United States • Anaheim, California, United States • Anaheim, California, United States +79 more locations

CVR Registry Evaluating Flexitouch Plus and Conservative Care vs Conservative Care Only for Treatment of Lymphedema

Tailoring Mindfulness Interventions for Families Managing Chronic Health Conditions

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Find Trials by Condition in Maryland

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

Combination Study for High Risk Multiple Myeloma Patients

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Reference Values for Plasma Catechols

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

The National Standard for Normal Fetal Growth

Repeat Antenatal Steroids Trial

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

PERL Continuous Glucose Monitoring (CGM) Study

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors